about
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myelomaAdditional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma patientsTowards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapyWaldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes.Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a GruppHypersplenism in liver disease and SLE revisited: current evidence supports an active rather than passive process.Therapeutic targeting and rapid mobilization of endosteal HSC using a small molecule integrin antagonist.Stem cell mobilization in HIV seropositive patients with lymphoma.Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in.Novel strategies for blood stem cell mobilization: special focus on plerixafor.How we mobilize haemopoietic stem cells.Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.Novel agents and approaches for stem cell mobilization in normal donors and patients.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.Cellular therapies supplement: strategies for improving transplant efficiency in the context of cellular therapeutics.Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic?Hematopoietic Stem Cell Mobilization and Homing after Transplantation: The Role of MMP-2, MMP-9, and MT1-MMP.A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean mulPlerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Evaluation of peripheral blood CD34+ cell count in the acute phase of traumatic brain injury and chest trauma.New agents in HSC mobilization.Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.Current options to manage Waldenström's macroglobulinemia.Release of matrix metalloproteinase-8 during physiological trafficking and induced mobilization of human hematopoietic stem cells.Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital.Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche.Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.New strategies for stem cell mobilization.Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization.
P2860
Q24186469-B8359B37-C212-4508-B7FE-A53CA52260A7Q24202384-370FE0BC-0D98-44C9-BE3B-F62763F4FC61Q26771159-51A6C7C3-A27F-422A-AC2A-05173F02344EQ33395066-707C9EFB-0D10-401E-BF76-7BC2E95B3F71Q33400780-CD4AF788-6BB9-4AA2-A8CB-E5BF84734FB7Q33408517-BC0420B4-AA56-472A-86A7-F4583FB98A90Q33421444-67610CC2-BDDD-4F33-96C9-4900DD9FC4A0Q35041174-5CFFF8BC-8094-4B43-B335-5576C9560790Q35588325-2E2F55AF-066D-4F74-AB5D-8062C1C0C716Q35920464-B0799BFC-CE2F-4A31-90A7-40D8EC972A35Q36698963-F0D1A4DE-D614-4544-A1DB-6BA4BC5E2B35Q37273199-F7F2FEFE-D0B4-4C95-B57F-7079D4CC4F66Q37429248-324B34F8-FD1E-4BE8-B1E6-3135F1DF3752Q37619537-B2FF2F92-7EF1-4270-8A1B-5964604DABA5Q37852914-157CB03F-5FEC-4C50-A0AB-4BB26B67432BQ37909447-1CB37553-B43A-4BB7-BBC4-6DC868D68918Q37914921-03D0A008-7B4E-41EA-9199-B046EDE00517Q37923308-58C3A8E1-C0ED-412F-B135-514FD5BB6DA1Q37923309-5FDE6C13-049B-4B0B-9B6F-3D69565A8809Q37943423-B3C5483D-C6D8-47CF-B861-FF9DDB9279B7Q37954790-B15061EA-B70E-48F7-BF46-4EF8987A8CF3Q37964485-D6BA07FE-F365-43B9-AAE2-9D9FFCCEB3FDQ38002032-2EE5D567-B6D6-4119-BB99-D8225B22BE01Q38194916-24EA411E-D2CB-4B2B-A9B3-713B6921BF03Q38199707-3749F5E2-8EAB-47AB-AF98-EDAA7E23189FQ38200909-E7006D9D-A058-4386-90D7-775E73E5A7E9Q38418369-5A0482D9-30FF-4272-BA9E-32035DC75F5FQ38880504-D1468B19-12A2-4161-A3C3-2E9AF41023B8Q38933942-14FAE2EA-FFC2-41A8-AEDA-21999613FFBCQ39025249-16B909F9-F2AD-41B5-9A52-3C1662DB7E06Q39066209-E5C70AAA-07E2-4CDC-9194-8BEFFD4F500FQ39358109-581C6F98-EF48-4485-828D-3EBD94840B69Q39934570-E9A2668E-4138-4612-8A89-312C64DA526EQ40056963-B9C32B45-0050-46FE-A821-304E664A1BA2Q40077907-DD711B75-3F69-4F7E-9982-DCD6138B89B3Q40896003-7C95EAD8-F10C-4BAA-B864-DF86B2A77E6FQ41104670-98FC946E-AD04-4A26-9174-E33584F81BC5Q41274044-ACA0A348-06F9-4EB2-9304-951F1527E0C9Q41694417-C0F2B2E7-6E3F-43AD-B31A-6F2A27394EC0Q42133489-591BFE2C-5359-4B11-9220-65B1E0EFF6A4
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status of stem cell mobilization.
@en
Current status of stem cell mobilization.
@nl
type
label
Current status of stem cell mobilization.
@en
Current status of stem cell mobilization.
@nl
prefLabel
Current status of stem cell mobilization.
@en
Current status of stem cell mobilization.
@nl
P1476
Current status of stem cell mobilization.
@en
P304
P356
10.1111/J.1365-2141.2010.08313.X
P407
P577
2010-09-01T00:00:00Z